Brain-derived neurotrophic factor blood levels are decreased in schizophrenia patients and associate with rs6265 genotypes

Clinical Biochemistry

Volumn 47, Issue 12, 2014, Pages 1052-1055

  Zakharyan, Roksana ^a   Boyajyan, Anna ^a  

^a INSTITUTE OF ORGANIC CHEMISTRY   (Armenia)

Author keywords

Brain derived neurotrophic factor; Plasma levels; Rs6265 Polymorphism; Schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; NEUROLEPTIC AGENT;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE CELL PLASTICITY; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; SCHIZOPHRENIA; BLOOD; GENETICS; MIDDLE AGED;

ADULT; BRAIN-DERIVED NEUROTROPHIC FACTOR; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA;

EID: 84905727023     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2014.03.021     Document Type: Article

References (43)

1. Zahir F.R., Brown C.J. Epigenetic impacts on neurodevelopment: pathophysiological mechanisms and genetic modes of action. Pediatr Res 2011, 69:92R-100R.
2. Guillin O., Demily C., Thibaut F. Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine. Int Rev Neurobiol 2007, 78:377-395.
3. Buckley P.F., Pillai A., Howell K.R. Brain-derived neurotrophic factor: findings in schizophrenia. Curr Opin Psychiatry 2011, 24:122-127.
4. Stanisz A.M., Stanisz J.A. Nerve growth factor and neuroimmune interactions in inflammatory diseases. Ann N Y Acad Sci 2000, 917:268-272.
5. Zhang X.Y., Zhou D.F., Wu G.Y., Cao L.Y., Tan Y.L., Haile C.N., et al. BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology 2008, 33:2200-2225.
6. Xiu M.H., Hui L., Dang Y.F., Hou T.D., Zhang C.X., Zheng Y.L., et al. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1508-1512.
7. Jindal R.D., Pillai A.K., Mahadik S.P., Eklund K., Montrose D.M., Keshavan M.S. Decreased BDNF in patients with antipsychotic naive first episode schizophrenia. Schizophr Res 2010, 119:47-51.
8. Thompson R.M., Weickert C.S., Wyatt E., Webster M.J. Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J Psychiatry Neurosci 2011, 36:195-203.
9. Yang Y.Q., Sun S., Yu Y.Q., Li W.J., Zhang X., Xiu M.H., et al. Decreased serum brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia. Neurosci Lett 2011, 502:37-40.
10. Noto C.S., Gadelha A., Belangero S.I., Smith M.A., de Aguiar B.W., Panizzuti B., et al. Association of biomarkers and depressive symptoms in schizophrenia. Neurosci Lett 2011, 505:282-285.
11. Green M.J., Matheson S.L., Shepherd A., Weickert C.S., Carr V.J. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry 2011, 16:960-972.
12. Rizos E.N., Papadopoulou A., Laskos E., Michalopoulou P.G., Kastania A., Vasilopoulos D., et al. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J Biol Psychiatry 2010, 11:251-255.
13. Niitsu T., Shirayama Y., Matsuzawa D., Hasegawa T., Kanahara N., Hashimoto T., et al. Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1836-1840.
14. Mackin P., Gallagher P., Watson S., Young A.H., Ferrier I.N. Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia. Aust N Z J Psychiatry 2007, 14:321-326.
15. Numata S., Ueno S., Iga J., Yamauchi K., Hongwei S., Ohta K., et al. Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism in schizophrenia is associated with age at onset and symptoms. Neurosci Lett 2006, 401:1-5.
16. Spalletta G., Morris D.W., Angelucci F., Rubino I.A., Spoletini I., Bria P., et al. BDNF Val66Met polymorphism is associated with aggressive behavior in schizophrenia. Eur Psychiatry 2010, 25:311-313.
17. Zakharyan R., Boyajyan A., Arakelyan A., Gevorgyan A., Mrazek F., Petrek M. Functional variants of the genes involved in neurodevelopment and susceptibility to schizophrenia in an Armenian population. Hum Immunol 2011, 72:746-748.
18. Gratacos M., Gonzalez J.R., Mercader J.M., de Cid R., Urretavizcaya M., Estivill X. Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirms association to substance-related disorders, eating disorders, and schizophrenia. Biol Psychiatry 2007, 61:911-922.
19. Kanazawa T., Glatt S.J., Kia-Keating B., Yoneda H., Tsuang M.T. Meta-analysis reveals no association of the Val66Met polymorphism of brain-derived neurotrophic factor with either schizophrenia or bipolar disorder. Psychiatr Genet 2007, 17:165-170.
20. Zhang X.Y., Tan Y.L., Zhou D.F., Cao L.Y., Wu G.Y., Xu Q., et al. Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics. J Psychiatr Res 2007, 41:997-1004.
21. Gallinat J., Schubert F., Bruhl R., Hellweg R., Klar A.A., Kehrer C., et al. Met carriers of BDNF Val66Met genotype show increased N-acetylaspartate concentration in the anterior cingulate cortex. Neuroimage 2010, 49:767-771.
22. Bhang S., Ahn J.H., Choi S.W. Brain-derived neurotrophic factor and serotonin transporter gene-linked promoter region genes alter serum levels of brain-derived neurotrophic factor in humans. Affect Disord 2011, 128:299-304.
23. Lang U.E., Hellweg R., Sander T., Gallinat J. The Met allele of the BDNF Val66Met polymorphism is associated with increased BDNF serum concentrations. Mol Psychiatry 2009, 14:120-122.
24. Terracciano A., Piras M.G., Lobina M., Mulas A., Meirelles O., Sutin A.R., et al. Genetics of serum BDNF: meta-analysis of the Val66Met and genome-wide association study. World J Biol Psychiatry 2013, 14:583-589.
25. Yin D.M., Chen Y.J., Sathyamurthy A., Xiong W.C., Mei L. Synaptic dysfunction in schizophrenia. Adv Exp Med Biol 2012, 970:493-516.
26. Drexhage R.C., Weigelt K., van Beveren N., Cohen D., Versnel M.A., Nolen W.A., et al. Immune and neuroimmune alterations in mood disorders and schizophrenia. Int Rev Neurobiol 2011, 101:169-201.
27. Silva A.J. Molecular and cellular cognitive studies of the role of synaptic plasticity in memory. J Neurobiol 2003, 54:224-237.
28. Takamiya K. Molecular mechanisms of synaptic plasticity underlying learning and memory. Seikagaku 2011, 83:1016-1026.
29. Maier S.F. Bi-directional immune-brain communication: implications for understanding stress, pain, and cognition. Brain Behav Immun 2003, 17:69-85.
30. Diamond B., Kowal C., Huerta P.T., Aranow C., Mackay M., DeGiorgio L.A., et al. Immunity and acquired alterations in cognition and emotion: lessons from SLE. Adv Immunol 2006, 89:289-320.
31. Sharma T., Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. J Psychopharmacol 2003, 17:89-95.
32. Zhang X.Y., Chen da C., Xiu M.H., Haile C.N., Luo X., Xu K., et al. Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls. Hum Genet 2012, 131(7):1187-1195.
33. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV-TR axis I disorders, non-patient edition (SCID-I/NP) 2001, Biometrics Research, New York State Psychiatric Institute, New York.
34. Zhang X.Y., Zhang W.F., Zhou D.F., Chen da C., Xiu M.H., Wu H.R., et al. Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba. Biol Psychiatry 2012, 72:700-706.
35. Ikeda Y., Yahata N., Ito I., Nagano M., Toyota T., Yoshikawa T., et al. Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia. Schizophr Res 2008, 101:58-66.
36. Chen da C., Wang J., Wang B., Yang S.C., Zhang C.X., Zheng Y.L., et al. Decreased levels of serum brain-derived neurotrophic factor in drug-naive first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl) 2009, 207:375-380.
37. Rizos E.N., Michalopoulou P.G., Siafakas N., Stefanis N., Douzenis A., Rontos I., et al. Association of serum brain-derived neurotrophic factor and duration of untreated psychosis in first-episode patients with schizophrenia. Neuropsychobiology 2010, 62:87-90.
38. Rizos E.N., Siafakas N., Stefanis N., Douzenis A., Kontaxakis V., Laskos E., et al. Association of serum BDNF and val66met polymorphism of the brain-derived neurotrophic factor in a sample of first psychotic episode patients. Psychiatrike 2009, 20:297-304.
39. Sotiropoulou M., Mantas C., Bozidis P., Marselos M., Mavreas V., Hyphantis T., et al. BDNF serum concentrations in first psychotic episode drug-naive schizophrenic patients: associations with personality and BDNF Val66Met polymorphism. Life Sci 2013, 92:305-310.
40. Woo N.H., Teng H.K., Siao C.J., Chiaruttini C., Pang P.T., Milner T.A., et al. Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat Neurosci 2005, 8:1069-1077.
41. Yang J., Siao C.J., Nagappan G., Marinic T., Jing D., McGrath K., et al. Neuronal release of proBDNF. Nat Neurosci 2009, 12:113-115.
42. Nagappan G., Zaitsev E., Senatorov V.V., Yang J., Hempstead B.L., Lu B. Control of extracellular cleavage of ProBDNF by high frequency neuronal activity. Proc Natl Acad Sci U S A 2009, 106:1267-1272.
43. Holm M.M., Nieto-Gonzalez J.L., Vardya I., Vaegter C.B., Nykjaer A., Jensen K. Mature BDNF, but not proBDNF, reduces excitability of fast-spiking interneurons in mouse dentate gyrus. J Neurosci 2009, 29:12412-12418.